Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status

Allogeneic stem cell transplantation (allo-SCT) is a potential cure for patients with malignant lymphoma that is based on the graft-versus-lymphoma (GVL) effect. Myeloablative conditioning allo-SCT is associated with high mortality and morbidity, particularly in patients older than 45 years, heavily...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Le, Zhang, Yi-Zhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643681/
https://www.ncbi.nlm.nih.gov/pubmed/23691438
http://dx.doi.org/10.7497/j.issn.2095-3941.2013.01.001
_version_ 1782268355927867392
author Zhang, Le
Zhang, Yi-Zhuo
author_facet Zhang, Le
Zhang, Yi-Zhuo
author_sort Zhang, Le
collection PubMed
description Allogeneic stem cell transplantation (allo-SCT) is a potential cure for patients with malignant lymphoma that is based on the graft-versus-lymphoma (GVL) effect. Myeloablative conditioning allo-SCT is associated with high mortality and morbidity, particularly in patients older than 45 years, heavily pretreated patients (prior hematopoietic stem cell transplantation or more than two lines of conventional chemotherapy) or patients affected by other comorbidities. Therefore, conventional allo-SCT is restricted to younger patients (<50 to 55 years) in good physical condition. Over the last decade, allo-SCT with reduced-intensity conditioning (RIC-allo-SCT) has been increasingly used to treat patients with lymphoma. This treatment is associated with lower toxicity and substantial decrease in the incidence of transplant-related mortality, and has the potential to lead to long-term remissions. Therefore, patients who are not suitable to undergo conventional allo-SCT can benefit from the potentially curative GVL effects of allo-SCT. Although RIC-allo-SCT has improved the survival of lymphoma patients, high post-transplant relapse rates or disease progression mainly results in treatment failure. Thus, further improvement is clearly needed. The role and timing of RIC-allo-SCT in the treatment of lymphoma remains unclear. Therefore, more prospective studies should clarify the effectiveness of this method. In this article, we review the recent literature on RIC-allo-SCT as a treatment for major lymphoma subtypes. Areas that require further investigation in the context of clinical trials are also highlighted.
format Online
Article
Text
id pubmed-3643681
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Chinese Anti-Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-36436812013-05-20 Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status Zhang, Le Zhang, Yi-Zhuo Cancer Biol Med Review Allogeneic stem cell transplantation (allo-SCT) is a potential cure for patients with malignant lymphoma that is based on the graft-versus-lymphoma (GVL) effect. Myeloablative conditioning allo-SCT is associated with high mortality and morbidity, particularly in patients older than 45 years, heavily pretreated patients (prior hematopoietic stem cell transplantation or more than two lines of conventional chemotherapy) or patients affected by other comorbidities. Therefore, conventional allo-SCT is restricted to younger patients (<50 to 55 years) in good physical condition. Over the last decade, allo-SCT with reduced-intensity conditioning (RIC-allo-SCT) has been increasingly used to treat patients with lymphoma. This treatment is associated with lower toxicity and substantial decrease in the incidence of transplant-related mortality, and has the potential to lead to long-term remissions. Therefore, patients who are not suitable to undergo conventional allo-SCT can benefit from the potentially curative GVL effects of allo-SCT. Although RIC-allo-SCT has improved the survival of lymphoma patients, high post-transplant relapse rates or disease progression mainly results in treatment failure. Thus, further improvement is clearly needed. The role and timing of RIC-allo-SCT in the treatment of lymphoma remains unclear. Therefore, more prospective studies should clarify the effectiveness of this method. In this article, we review the recent literature on RIC-allo-SCT as a treatment for major lymphoma subtypes. Areas that require further investigation in the context of clinical trials are also highlighted. Chinese Anti-Cancer Association 2013-03 /pmc/articles/PMC3643681/ /pubmed/23691438 http://dx.doi.org/10.7497/j.issn.2095-3941.2013.01.001 Text en 2013 Cancer Biology & Medicine This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
spellingShingle Review
Zhang, Le
Zhang, Yi-Zhuo
Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status
title Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status
title_full Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status
title_fullStr Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status
title_full_unstemmed Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status
title_short Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status
title_sort reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643681/
https://www.ncbi.nlm.nih.gov/pubmed/23691438
http://dx.doi.org/10.7497/j.issn.2095-3941.2013.01.001
work_keys_str_mv AT zhangle reducedintensityconditioningallogeneicstemcelltransplantationinmalignantlymphomacurrentstatus
AT zhangyizhuo reducedintensityconditioningallogeneicstemcelltransplantationinmalignantlymphomacurrentstatus